TECVAYLI 10 mg/mL solution for injection

DRUG3 trials

Sponsors

Fundacion Pethema, Takeda Development Center Americas Inc., Region Hovedstaden

Conditions

Haematological diseases; any disorder that primarily affects the bloodMultiple MyelomaPrimary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapybone marrowthe lymphatic system and/or blood-forming organs.

Phase 2

An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab) in the frontline therapy of newly diagnosed high-risk multiple myeloma

Active, not recruitingCTIS2024-514016-26-00

Fundacion PethemaMultiple Myeloma

Start: 2023-06-22Target: 30Updated: 2025-05-07

Phase 3

A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen×CD3–Directed Bispecific Antibody Therapy

Not yet recruitingCTIS2024-518420-80-00

Takeda Development Center Americas Inc.Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy

Target: 143Updated: 2026-01-12

Phase 4

A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol

Not yet recruitingCTIS2026-525658-13-00

Region Hovedstadenbone marrow, Haematological diseases; any disorder that primarily affects the blood, the lymphatic system and/or blood-forming organs.

Target: 200Updated: 2026-06-25